Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (2)

Zachary Karl, Vice President Business Development @ Bio Innovations Midwest 2025
press clippingsvideo
World Bio Markets: AI - A tool U.S. industrial biomanufacturing cannot ignoreOctober 8, 2025
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health Epidemic
heltzeninvestorpress clippingsvideo
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health EpidemicSeptember 18, 2025
The challenges of SynBio
video
The challenges of SynBioSeptember 15, 2025
Transcript: Q2 2025 Earnings Call
investorvideo
Transcript: Q2 2025 Earnings CallAugust 13, 2025
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscience
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
press releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not Dodge
press clippingsvideo
World Bio Markets: AI and Machine Learning - The Silver Bullet we Must Not DodgeJuly 2, 2025
Chris Marlett, MDB Capital
investorpress clippingsvideo
Slack Capital interview: Chris Marlett, Chairman of the BoardMay 22, 2025
Slack Capital interview: Damien Perriman, CCO
investorpress clippingsvideo
Slack Capital interview: Damien Perriman, CCOMay 20, 2025
Tyler Korman
investorpress clippingsvideo
Slack Capital interview: Tyler Korman, VP of ResearchMay 15, 2025
Previous page
Page 2 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark